Associate Professor of Surgery
University of California, Irvine, United States
Oliver Eng, MD, FACS, is a surgical oncologist and an Associate Professor in the Division of Surgical Oncology at the University of California, Irvine, where he is also Associate Director of the Peritoneal Surface Malignancy Program as well as the Complex General Surgical Oncology Fellowship. He is a double board-certified surgeon and surgical oncologist who focuses on the treatment of peritoneal metastases and in complex cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Dr. Eng has co-authored numerous peer-reviewed manuscripts in journals including Cancer Discovery, Cancer, British Journal of Cancer, and JAMA Surgery. He has received both extramural and intramural funding for his research, which centers on better understanding the molecular and immunologic characteristics of peritoneal tumors. His research aims to develop innovative therapies for metastatic disease and optimize outcomes and care in cancer patients. He has presented his work nationally and internationally, and he has served as a principal investigator or co-investigator on multiple clinical trials. Dr. Eng serves on the editorial board for a variety of scientific journals and has been appointed to a number of national committees. He is a member of the SSO Training Committee, a Faculty Advisor to the Fellows and Young Attendings Subcommittee, and is a member of the SCORE Committee.
Aileron Therapeutics Inc (Individual(s) Involved: Self): Stockholder; Alpine Immune Sciences (Individual(s) Involved: Self): Stockholder; ALX Oncology Holdings Inc (Individual(s) Involved: Self): Stockholder; Arbutus Biopharma Corp (Individual(s) Involved: Self): Stockholder; ARK Funds (Individual(s) Involved: Self): Stockholder; Cerevel Therapeutics Holdings Inc (Individual(s) Involved: Self): Stockholder; Iovance Biotherapeutics (Individual(s) Involved: Self): Stockholder; Mediwound Ltd (Individual(s) Involved: Self): Stockholder; Novavax, Inc. (Individual(s) Involved: Self): Stockholder; Phathom Pharmaceuticals Inc (Individual(s) Involved: Self): Stockholder; Tarsus Pharmaceuticals Inc (Individual(s) Involved: Self): Stockholder; Veru Inc (Individual(s) Involved: Self): Stockholder; Zymeworks Inc (Individual(s) Involved: Self): Stockholder
Saturday, March 12, 2022
11:10 AM – 12:00 PM CST